COVAX

COVAX
Name	COVAX
Type	Global health initiative
Founded	2020
Key people	Tedros Adhanom Ghebreyesus, Seth Berkley, Richard Hatchett
Parent	World Health Organization, Gavi, the Vaccine Alliance, Coalition for Epidemic Preparedness Innovations
Website	https://www.gavi.org/covax-facility

COVAX. It is a worldwide initiative aimed at ensuring equitable access to COVID-19 vaccines, particularly for lower-income nations. Co-led by the World Health Organization, Gavi, the Vaccine Alliance, and the Coalition for Epidemic Preparedness Innovations, its primary goal was to accelerate the development and manufacture of vaccines while guaranteeing fair distribution. The facility was established as a critical pillar of the Access to COVID-19 Tools Accelerator, a global collaboration launched in response to the COVID-19 pandemic.

Background and establishment

The initiative was conceived in early 2020 as the scale of the COVID-19 pandemic became clear, highlighting the risk of vaccine nationalism where wealthy countries would secure the majority of doses. Key global health leaders, including Tedros Adhanom Ghebreyesus of the World Health Organization, advocated for a coordinated international response. The formal announcement came in April 2020 as part of the broader Access to COVID-19 Tools Accelerator, with founding partners Gavi, the Vaccine Alliance and the Coalition for Epidemic Preparedness Innovations taking operational roles. The establishment was supported by numerous governments and philanthropic organizations, including the Bill & Melinda Gates Foundation, and was endorsed during events like the World Health Assembly.

Structure and governance

The governance framework involves a complex partnership between the three core agencies: the World Health Organization provides normative guidance and technical oversight, Gavi, the Vaccine Alliance manages financing and procurement, and the Coalition for Epidemic Preparedness Innovations focuses on research and development. A senior leadership team, including Seth Berkley of Gavi and Richard Hatchett of CEPI, oversees daily operations. Key decision-making bodies include the Gavi Board and advisory groups comprising representatives from participating countries, UNICEF, the World Bank, and civil society organizations. This structure was designed to integrate the expertise of entities like the African Union and the European Commission.

Funding and financial mechanisms

Financing was secured through a combination of sovereign donations, private philanthropy, and multilateral development banks. Major donors included the United States, the European Union, Germany, the United Kingdom, and Japan, alongside contributions from the Bill & Melinda Gates Foundation. The World Bank and the International Monetary Fund provided significant funding and financial instruments to support procurement. A key innovation was the COVAX Advance Market Commitment, a financing mechanism designed to guarantee a market for vaccine manufacturers while subsidizing costs for eligible lower-income economies. Fundraising efforts were championed at global events like the Global Citizen Live concert.

Vaccine allocation and distribution

Allocation was guided by a framework developed by the World Health Organization which initially aimed to provide doses for approximately 20% of the population in all participating countries, focusing on frontline health workers and high-risk groups. The distribution utilized the existing logistics networks of UNICEF and the Pan American Health Organization. Vaccines from manufacturers like AstraZeneca, Pfizer–BioNTech, and Johnson & Johnson were shipped globally, with early deliveries reaching countries such as Ghana, Côte d'Ivoire, and Colombia. The initiative worked in tandem with regional efforts like the African Vaccine Acquisition Trust.

Challenges and criticisms

The facility faced significant hurdles, including severe supply constraints due to export restrictions from major producing countries like India and manufacturing delays at sites such as the Serum Institute of India. It was criticized for slow rollout and being outpaced by bilateral agreements between wealthy nations and companies like Moderna. Ethical debates arose over the allocation formula and the perceived power of donor countries within the Gavi Board. Additional logistical challenges included cold-chain requirements for vaccines like Pfizer–BioNTech and vaccine hesitancy in regions such as the Democratic Republic of the Congo.

Impact and outcomes

Despite challenges, the program delivered over 1.9 billion vaccine doses to 146 participating economies by early 2023, providing the primary source of vaccines for many lower-income countries. It helped initiate vaccination campaigns in nations from Fiji to Rwanda and supported the establishment of vaccination sites in conflict zones like Yemen. The initiative also bolstered regional manufacturing capacity through partnerships with entities like Aspen Pharmacare in South Africa. Its model influenced subsequent global health discussions on pandemic preparedness at forums like the G7 and the World Health Assembly.

Category:COVID-19 pandemic Category:World Health Organization Category:Vaccination